hera-gitrl (Apogenix Inc)
90
Structured Review
Apogenix Inc
hera-gitrl
Hera Gitrl, supplied by Apogenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl/hera+gitrl/pmc06220479-6906-22-2
Average 90 stars, based on 1 article reviews
Hera Gitrl, supplied by Apogenix Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl/hera+gitrl/pmc06220479-6906-22-2
Average 90 stars, based on 1 article reviews
hera-gitrl - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Binding Assay:Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: To overcome the limitations of Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: Article Title: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Article Snippet: Based on Article Title: The promise and challenges of immune agonist antibody development in cancer. Article Snippet: | Immune cell functions are regulated by co‐inhibitory and co‐stimulatory receptors.. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4).. Looking ahead, there is substantial promise in targeting co‐stimulatory receptors with agonist antibodies, and a growing number of these agents are making their way through various stages of development. In Vivo:Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: To overcome the limitations of Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: Article Title: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Article Snippet: Based on Article Title: The promise and challenges of immune agonist antibody development in cancer. Article Snippet: | Immune cell functions are regulated by co‐inhibitory and co‐stimulatory receptors.. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4).. Looking ahead, there is substantial promise in targeting co‐stimulatory receptors with agonist antibodies, and a growing number of these agents are making their way through various stages of development. Activation Assay:Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: To overcome the limitations of Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: Article Title: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Article Snippet: Based on Article Title: The promise and challenges of immune agonist antibody development in cancer. Article Snippet: | Immune cell functions are regulated by co‐inhibitory and co‐stimulatory receptors.. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4).. Looking ahead, there is substantial promise in targeting co‐stimulatory receptors with agonist antibodies, and a growing number of these agents are making their way through various stages of development. Functional Assay:Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: To overcome the limitations of Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge Article Snippet: Article Title: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Article Snippet: Based on Article Title: The promise and challenges of immune agonist antibody development in cancer. Article Snippet: | Immune cell functions are regulated by co‐inhibitory and co‐stimulatory receptors.. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4).. Looking ahead, there is substantial promise in targeting co‐stimulatory receptors with agonist antibodies, and a growing number of these agents are making their way through various stages of development. |
![Fig. 5. Histoscores of GITRL expression on thyroid follicular cells from patients with AITD (GD [black circle] and HD [white circle]) and healthy subjects. Wilcoxon test is used to compare differences in histoscores between AITD pa tients and healthy subjects.](https://pub-med-unpaywalled-images-cdn.bioz.com/pub_med_ids_ending_with_2445/pm40412445/pm40412445__page4_image2.jpg)
![Fig. 6. Serum titers of (A) TgAb or (B) McAb in AITD patients (GD [black circle] and HD [white circle]) with each histoscore of GITRL expression on thyroid follicular cells. Mann–Whitney U test is used to compare differences in TgAb or McAb between patients with AITD showing diverse histoscores.](https://pub-med-unpaywalled-images-cdn.bioz.com/pub_med_ids_ending_with_2445/pm40412445/pm40412445__page5_image1.jpg)